NEW YORK CITY (dpa-AFX) - Philip Morris International Inc. (PM) announced that the U.S. Food and Drug Administration (FDA) has issued Marketing Granted Orders to its U.S. affiliate, Swedish Match USA, Inc. The authorization covers 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review.
These decisions build on the FDA's earlier authorizations of ZYN products across multiple flavors and in both 3mg and 6mg strengths, further expanding the portfolio available in the U.S. market.
Philip Morris International closed Friday's regular trading at $188.23, down $3.29 or 1.72%, on the NYSE.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
